People living with HIV under antiretroviral treatment show enhanced cardiovascular risk. A recent study by our team, led by Tania Quesada, Marta Giralt and Ruben Cereijo in collaboration with Pere Domingo from Hospital de la Santa Creu i Sant Pau, highlights the potential of abnormally reduced CXCL14 levels as a subclinical biomarker of cardiovascular disease in people living with HIV. The study has just been published in the European Journal of Pharmacology (Volume 1003, 15 September 2025, 177996 ). Click here for access to the video provided by the Cell Biologist platform, summarizing these findings.